Company Information

  

Address: 4640 SW MACADAM AVENUE
SUITE 270 
City: PORTLAND 
State: OR 
Zip Code: 97239 
Telephone: 855 855 GALE 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "Company") is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company's pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax(TM) (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.27NAN/E
03/20170.26NA2.35
12/2016-1.11NAN/E
09/2016-48.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.07Total Liab/Total Assets0.56
Net Inc/Total Assets-0.36Total Liab/Inv Cap2.06
Net Inc/Inv Cap-1.30Total Liab/Comm Equity0.11
Pretax Inc/Net SalesNAInterest Coverage Ratio-2.10
Net Inc/Net SalesNACurr Debt/Equity0.61
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.61
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio1.23
Inventory TurnoverNACurrent Ratio1.23
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.87 2.73 2.52 2.85
Operating Income -4.91 -5.09 -7.14 -6.47
Interest Exp 0.69 0.97 1.52 1.38
Pretax Income -7.10 -2.28 -1.69 -4.34
Other Income -1.50 3.78 6.96 3.51
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.40 -11.72 -5.52 -6.93

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 31.67 41.23 36.11 43.42
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 32.29 42.05 37.50 44.46
Net Property, Plant & Equipment 0.15 0.17 0.20 0.23
Total Assets 60.55 70.33 65.81 72.85
Liabilities        
Accounts Payable 3.02 4.35 5.13 4.71
Debt in Current Liabilities 14.33 13.55 17.35 23.72
Total Current Liabilities 34.54 36.27 30.40 42.54
Long-Term Debt NA NA NA NA
Total Liabilities 41.43 43.14 37.15 48.92
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.02 0.02
Retained Earnings -323.05 -314.65 -302.93 -297.42
Treasury Stock -3.85 -3.85 -3.85 -3.85
Total Stockholders' Equity 19.13 27.19 28.66 23.93
Total Liabilities and Stockholders' Equity 60.55 70.33 65.81 72.85

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -9.56 -10.40 -8.00 -12.21
Net Cash Provided by Investing Activities -0.01 -0.02 0.00 0.00
Net Cash Provided by Financing Activities 0.00 19.98 1.57 17.13

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-34.97--
12/20130.00-76.68--
12/20140.00-36.61--
12/20150.00-63.90--
12/20160.00-23.55-1.11
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17697,87020.49




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.